Research ArticleANTIBODIES

Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes

See allHide authors and affiliations

Science Immunology  22 Feb 2019:
Vol. 4, Issue 32, eaav5062
DOI: 10.1126/sciimmunol.aav5062

Engaging monocytes to battle chikungunya

Antibody-binding receptors, including Fc receptors and complement receptors, play a central role in mediating antibody-dependent immune activation. Here, Fox et al. have examined the role of Fcγ receptors and complement component 1q (C1q) in meditating the therapeutic effects of monoclonal IgG antibodies targeting chikungunya virus. Using antibody engineering in conjunction with mouse strains lacking C1q or Fcγ receptors, they report that the therapeutic effects of these antibodies are dependent on expression of Fcγ receptors. Furthermore, by depleting distinct immune cell types, they found that engagement of Fc receptors on monocytes is central in driving antibody-dependent clearance of chikungunya virus.

View Full Text

Stay Connected to Science Immunology